Viewpoint p27^{KIP1} phosphorylation by PKB/Akt leads to poor breast cancer prognosis

Robert B Clarke

Breast Biology Group, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, UK

Corresponding author: Robert B Clarke (e-mail: RClarke@PICR.man.ac.uk)

Published: 31 March 2003

Breast Cancer Res 2003, **5**:162-163 (DOI 10.1186/bcr596) © 2003 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X)

Introduction

Three papers published concurrently in the October issue of *Nature Medicine* have demonstrated new links between mitogenic cytokine signalling and the cell cycle inhibitor p27^{KIP1}, and have elucidated how this link may contribute to breast cancer patient prognosis [1–3].

Cell cycle control occurs through cyclin binding to the cyclin-dependent kinases (CDKs) that stimulate G1 progression [4]. p27^{KIP1} is a member of the kinase inhibitor protein (KIP) family that inhibit cell cycle progression by binding to cyclin-CDK complexes [5]. In cancers where protein kinase B (PKB)/Akt is constitutively activated by upstream oncogenes, Akt decreases p27^{KIP1} by increasing proteolysis and reducing transcription [6].

These three articles describe a third way in which Akt resists G1 arrest, namely by a p27^{KIP1} phosphorylation that impairs nuclear import and prevents its inhibition of cyclin-CDK complexes. The authors of these studies conclude that exclusion of p27^{KIP1} from the nucleus leads to a poor patient outcome in breast cancer [1-3].

p27^{KIP1} phosphorylation leads to cytoplasmic localisation

Wild type and constitutively active Akt were both shown to phosphorylate p27^{KIP1} at threonine157, leading to cytoplasmic localisation of p27^{KIP1}. Blockade of Akt activation by the phosphatidyl inositol 3'-kinase (PI3K) inhibitor LY294002, or transfection with the mutant p27^{KIP1}. T157A, led to nuclear p27^{KIP1} localisation. Constitutively active Akt prevented wild type p27^{KIP1}, but not p27^{KIP1}. T157A, from causing G1 arrest.

In two of the studies it was reported that approximately 40% of primary breast tumours displayed cytoplasmic p27^{KIP1} staining [1,3]. The presence of cytoplasmic

p27^{KIP1} in human breast cancers was highly correlated with Akt activation. The best prognostic subgroup of breast tumours had strong, exclusively nuclear p27^{KIP1} staining, while cancers with lower expression levels, but cytoplasmic localisation, had the worst survival rates.

The data indicate that $p27^{KIP1}$ normally acts as a tumour suppressor protein, but that the oncogenic activation of Akt leads to mislocation of $p27^{KIP1}$ to the cytoplasm where it is unable to inhibit cell cycle proteins. The study indicates that cytoplasmic location of $p27^{KIP1}$ in breast tumours is a prognostic indicator and that the Akt pathway may be a good target for anti-cancer therapy.

Conclusion

p27^{KIP1} is an inhibitor of cell cycle progression that is rarely mutated or silenced in cancers. The *Nature Medicine* articles demonstrate that p27^{KIP1} depends on a nuclear location to perform its cell cycle inhibitory function and that Akt phosphorylates p27^{KIP1} leading to its mislocalisation in the cytoplasm [1–3].

Akt lies downstream of PI3K and the growth factor receptors epidermal growth factor receptor (EGFR) and ErbB2, which act as oncogenes in numerous cancers [7]. This means that Akt is commonly activated in many forms of cancer [8]. All three of these studies confirm that the action of Akt on p27^{KIP1} localisation appears crucial to breast tumour progression [1–3]. There is evidence that Akt can also exclude nuclear presence of another cell cycle inhibitor, p21^{CIP1} [9]. It will be interesting to see whether the cellular location of p21^{CIP1} will add to the prognostic information given by p27^{KIP1} in cancers.

Finally, the articles suggest new therapeutic opportunities in targeting Akt or the $p27^{KIP1}$ phosphorylation site to relocate $p27^{KIP1}$ to the nucleus and improve the long-term

prognosis of breast cancer patients in whom this important cell cycle regulator is mislocated.

Competing interests

None declared.

References

- Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-1160.
- 2. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002, 8:1145-1152.
- Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, 3. Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclindependent kinase inhibitor p27^{Kip1} by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8:1136-1144
- Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13: 1501-1512
- 5. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994, 14:3683-3694. Slingerland J, Pagano M: Regulation of the cdk inhibitor p27
- 6. and its deregulation in cancer. J Cell Physiol 2000, 183:10-17.
- 7. Sun H, Lesche R, Li DM, Liliental J, Zhang JH, Gao J, Gavrilova N, Mueller B, Liu X, Wu H: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1999, 96:6199-6204.
- Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001, 98:10983-10985.
- Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC: Cytoplas-mic localization of p21^{cip1/WAF1} by Akt-induced phosphorylaq tion in HER-2/neu-overexpressing cells. Nat Cell Biol 2001, 3: 245-252.

Note

This article is based on papers highlighted by Faculty of 1000 (http://www.facultyof1000.com/start.asp), a web-based literature awareness service. Faculty of 1000 evaluations available for articles cited in this report may be viewed at: http://breast-cancer-research.com/reports/bcr596.asp

Correspondence

Robert B Clarke, Breast Biology Group, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, UK. E-mail: RClarke@PICR.man.ac.uk